RT Journal Article
T1 MicroRNAs in T Cell-Immunotherapy
A1 Dosil, Sara
A1 Rodríguez-Galán, Ana
A1 Sánchez-Madrid, Francisco
A1 Fernández Messina, Lola María
AB MicroRNAs (miRNAs) act as master regulators of gene expression in homeostasis and disease. Despite the rapidly growing body of evidence on the theranostic potential of restoring miRNA levels in pre-clinical models, the translation into clinics remains limited. Here, we review the current knowledge of miRNAs as T-cell targeting immunotherapeutic tools, and we offer an overview of the recent advances in miRNA delivery strategies, clinical trials and future perspectives in RNA interference technologies.
PB MDPI
YR 2022
FD 2022
LK https://hdl.handle.net/20.500.14352/97239
UL https://hdl.handle.net/20.500.14352/97239
LA eng
NO Dosil, S.G.; Rodríguez-Galán, A.; Sánchez-Madrid, F.; Fernández-Messina, L. MicroRNAs in T Cell-Immunotherapy. Int. J. Mol. Sci. 2023, 24, 250. https://doi.org/10.3390/ijms24010250
NO FundingThis manuscript was funded by grants AEI/10.13039/501100011033, PID-2020-120412RB-I100 and PDC2021-121797-I00 (F.S.-M.) from the Spanish Ministry of Economy and Competitiveness; CAM (S2017/BMD-3671-INFLAMUNE-CM) from the Comunidad de Madrid (F.S.-M.), CIBERCV (CB16/11/00272) and BIOIMID PIE13/041 from the Instituto de Salud Carlos “la Caixa” Foundation under the project code HR17-00016. The current research is supported by AECC-Coordinated Grant 2022 (PRYCO223002PEIN). The CNIC is supported by the Ministerio de Ciencia, Innovacion y Universidades and the Pro-CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505). IMDEA Nanociencia acknowledges support from the ‘Severo Ochoa’ Programme for Centres of Excellence in R&D (MINECO, CEX2020-001039-S). S.G.D. is supported by a grant from the Spanish Ministry of Universities.
NO Comunidad de Madrid
NO Ministerio de Economía y Competitividad (España)
NO Ministerio de Ciencia, Innovación y Universidades (España)
DS Docta Complutense
RD 7 abr 2025